ALT on Nasdaq
Altimmune, Inc.
American biopharmaceutical company.1
$2.32 up 0.01 (0.53%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 18, 2026.
Overview
1997Founded1
Compare with NEONC TECHNOLOGIES HOLDINGS, INC., AXIM BIOTECHNOLOGIES, INC. or ORAGENICS INC, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-230461.0%Operating margin5
-214861.0%Net margin5
105.0%Revenue growth, 20255
-39.2%Return on equity5
0.15×Debt to equity5
-$67.5MFree cash flow5
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development99¢$66.4M
- Income tax1¢$681.0K
Out of $41.0K in revenue.5 The company lost money this year.
Financial statements
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $5.8M6 | $8.2M7 | $4.4M7 | -$68.0K8 | $426.0K9 | $20.0K5 | $41.0K5 |
| Research and development | $17.8M6 | $49.8M7 | $74.5M10 | $70.5M8 | $65.8M9 | $82.2M5 | $66.4M5 |
| Operating income | -$21.5M6 | -$54.8M7 | -$96.9M10 | -$87.7M8 | -$95.9M9 | -$103.2M5 | -$94.5M5 |
| Interest | $2.2K6 | $9.4K7 | $5.0K10 | $8.0K8 | $35.0K8 | ||
| Income tax | -$58.5K6 | -$5.4M7 | -$197.0K8 | -$681.0K5 | |||
| Net income | -$20.5M6 | -$49.0M7 | -$97.1M10 | -$84.7M8 | -$88.4M9 | -$95.1M5 | -$88.1M5 |
| Earnings per share | -$1.917 | -$2.3510 | -$1.818 | -$1.669 | -$1.345 | -$1.005 | |
| Earnings per share (diluted) | -$1.917 | -$2.3510 | -$1.818 | -$1.669 | -$1.345 | -$1.005 |
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash | $9.0M6 | $115.9M7 | $190.3M10 | $111.1M8 | $135.1M9 | $36.9M5 | $43.8M5 |
| Current assets | $39.4M6 | $230.3M7 | $204.1M10 | $192.8M8 | $209.6M9 | $137.3M5 | $278.2M5 |
| Total assets | $54.1M6 | $245.1M7 | $218.9M10 | $206.9M8 | $210.6M9 | $139.3M5 | $279.9M5 |
| Current liabilities | $3.9M6 | $12.0M7 | $18.3M10 | $17.1M8 | $12.1M9 | $10.5M5 | $15.0M5 |
| Long-term debt | $1.9M6 | $1.8M7 | $1.5M10 | $4.6M10 | $34.3M5 | ||
| Total liabilities | $8.5M6 | $19.2M7 | $19.7M10 | $21.6M8 | $16.5M9 | $15.8M5 | $55.0M5 |
| Shareholders’ equity | $45.5M7 | $225.9M10 | $199.1M8 | $185.3M9 | $194.1M5 | $123.5M5 | $224.9M5 |
| Shares outstanding | 15.3M shares6 | 37.1M shares7 | 41.0M shares10 | 49.2M shares8 | 70.7M shares9 | 72.4M shares5 | 110.9M shares5 |
Former names
Timeline
- 1997Founded Founded1
Recent filings
- Oct 5, 20264
- Oct 5, 20264
- Oct 2, 20263
- Oct 2, 20264
- Sep 29, 20268-K
- Sep 17, 20264
- Aug 13, 20264
- Aug 12, 20268-K
- Aug 12, 202610-Q
- Aug 3, 20264
- Aug 3, 20264
- Jul 28, 20268-K
- Jun 16, 20268-K
- May 15, 2026SCHEDULE 13G/A
- May 13, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitealtimmune.com1
- X (Twitter)x.com/AltimmuneInc1
- LinkedInwww.linkedin.com/company/altimmune1
- WikidataQ30283539
- SEC EDGARCIK 1326190
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataAltimmune, Inc. on Wikidata
- 2SEC EDGARAltimmune, Inc. filings on SEC EDGAR
- 3Yahoo FinanceALT quote
- 4SEC EDGARAltimmune, Inc. filings on SEC EDGAR
- 5SEC EDGARAltimmune, Inc. 10-K for fiscal 2025
- 6SEC EDGARAltimmune, Inc. 10-K for fiscal 2019
- 7SEC EDGARAltimmune, Inc. 10-K for fiscal 2020
- 8SEC EDGARAltimmune, Inc. 10-K for fiscal 2022
- 9SEC EDGARAltimmune, Inc. 10-K for fiscal 2023
- 10SEC EDGARAltimmune, Inc. 10-K for fiscal 2021
- 11SEC EDGARAltimmune, Inc. 10-Q for fiscal 2026
- 12SEC EDGARAltimmune, Inc. 10-Q for fiscal 2026